She holds a Bachelor’s degree in Biology from the University of Mogi das Cruzes (UMC), a Master’s and PhD in Biotechnology from the University of São Paulo (USP), and a specialization in Vaccinology from the Institut Pasteur in Paris.
Since 2007, she has worked at the Butantan Institute, with extensive experience in vaccine production and industrial bioprocessing. She served as Head of the Aerobic Vaccines Section (2009–2019), Director of the Bacteriology Service (2019–2022), and is currently Technical Director of Production at the Bioindustrial Center.
She has played a key role in the production of active pharmaceutical ingredients (APIs) for bacterial vaccines, antigens for anti-toxin and rabies sera, as well as in the development and scale-up of new vaccine technologies, including pandemic influenza vaccines, human rabies vaccines, and adjuvanted vaccines.
She is responsible for technology transfer and internalization processes, including mRNA vaccine platforms and cell therapy manufacturing under GMP conditions.
She led the implementation of the IB160 nanoparticle emulsion adjuvant production process and contributed to the recovery of rabies antigen production for antiserum manufacturing.
She currently oversees production units for bacterial vaccines, rabies vaccines, the mRNA vaccine development area (CPR), and the Nutera-SP CAR-T cell therapy platform at the Butantan Institute.
She also served as Teaching Assistant for the course “Principles and Practice of Clinical Research” at Harvard T.H. Chan School of Public Health and has authored scientific publications, patents, and received multiple awards.
She currently serves as Technical Director of Production at the Bioindustrial Center, Butantan Institute.
